Global Markets for Treatments for Syndromes of Dementia andMovement DisordersReport Details:Published:September 2012No. of...
through 2017.Applications for syndromes of dementia and movement disorder treatments, or therapeutictechnologies, are also...
METHODOLOGYBCC conducted a comprehensive literature search, which included technical newsletters andjournals, and many oth...
Chapter- 3: Overview 10The BrainClassification Of Neurodegenerative DisordersNeurodegenerative DisordersDiagnostic Tests F...
Market By Type Of DiseaseMarkets By RegionRegional Markets By Disease TypeMarket By TechnologyIndustry StructureChapter- 1...
Cadila Healthcare Ltd.Caraco Pharmaceutical LaboratoriesCardinal HealthCellzome AgCipla Ltd.Cognition Therapeutics Inc.Col...
Newron Pharmaceuticals SpaNoscira SaNovartis AgNymox Pharmaceutical Corp.Orchid Chemicals & Pharmaceuticals Ltd.Orion Corp...
Table 1 : Classification Of Syndromes Of Dementia And Movement Disorders By PrimaryClinical/Pathological FeatureTable 2 : ...
Table 23 : Global Sales Of Drug Products Used To Treat Pick’s Disease By Region, Through 2017Table 24 : Global Sales Of Dr...
Disease Type, Through 2017Table 46 : Global Market Shares Of Drug Products Used To Treat Movement Disorder SyndromesBy Dis...
Type, 2010-March 2012Table 67 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia)By Patent ...
2017Figure 14 : Global Sales Of Drug Products Used To Treat Lewy Body Dementia By Region, 2010-2017Figure 15 : Global Sale...
2017Figure 36 : Global Sales Of Drug Products Used To Treat Multiple System Atrophy By Region,2010-2017Figure 37 : Global ...
Upcoming SlideShare
Loading in …5
×

Global Markets for Treatments for Syndromes of Dementia and Movement Disorders

193 views
162 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
193
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Global Markets for Treatments for Syndromes of Dementia and Movement Disorders

  1. 1. Global Markets for Treatments for Syndromes of Dementia andMovement DisordersReport Details:Published:September 2012No. of Pages: 228Price: Single User License – US$4850•The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach $11.1 billion in 2012. Total market value is expected to reach $16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.•Progressive dementia treatments are expected to have a value of $7.3 billion in 2012 and nearly $11 billion in 2017, a CAGR of 8.4%.•Treatments for movement disorders are expected to be worth $3.2 billion in 2012 and $4.8 billion in 2017, a CAGR of 8.3%.REPORT SCOPEINTRODUCTIONSTUDY OBJECTIVESBCC’s goal in conducting this study is to provide an overview of the current and futurecharacteristics of the global markets for treatments for syndromes of dementia and movementdisorders. The key objective is to present a comprehensive analysis and the future direction of themarket as it shapes drug and therapy development.This report explores present and future strategies within the neurodegenerative disorder market,which includes treatments and therapies for progressive dementia, progressive dementia withother neurological abnormalities and movement disorders. Market gains, setbacks and needs arediscussed in this report. Comparisons, usage and the advantages and disadvantages of differenttypes of technologies, including small molecules and monoclonal antibodies, are also presented inthis report.A detailed analysis of the structure of the syndromes of dementia and movement disorder industryhas been conducted. Revenues are broken down by neurodegenerative disease and primaryclinical/pathological feature. Sales figures are estimated for the five-year period from 2012
  2. 2. through 2017.Applications for syndromes of dementia and movement disorder treatments, or therapeutictechnologies, are also discussed separately in the report, with an emphasis on small molecule andmonoclonal antibodies technology. The report also covers significant patents and their allotmentin each category.REASONS FOR DOING THIS STUDYExtensive research in the field of syndromes of dementia and movement disorders and companycollaborations with research institutes have highlighted the importance of understanding the natureof these disorders. New technological developments are providing disease-modifying therapiesfor the late stages of the disorders. Collaborations between research institutes and pharmaceuticalcompanies are on the rise as state-of-the-art technology is being explored to develop moreefficient products and therapies.R&D spending, along with increasing competition, patent expiries and new technologies are takingthe market in a new direction. Global market revenues increased from 2009 to 2011 and areexpected to continue to show growth over the forecast period as new advances, launches andcollaborations continue to influence the market. This study looks at most of the systems affectedby these factors.Acquisition strategies and collaborations by companies are also covered in this report. This studyalso discusses the strength and weaknesses of each type of technology in light of the newtechnologies, growing competition and changing customer needs.CONTRIBUTIONS OF THE STUDY AND FOR WHOMThis study contributes to the areas of market growth in treatments for Alzheimer’s disease, Lewybody dementia, Pick’s disease, Huntington’s disease, corticobasal ganglionic degeneration,Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy and Hallervorden-Spatz disease. Pharmaceutical biotechnical companies, research institutes and physicians willfind this study to be of interest.SCOPE OF THE STUDYThe scope of this study encompasses the neurodegenerative disorders in the pharmaceutical andbiotechnology markets. BCC analyzes each market and its applications, regulatory environment,technology involved, market projections and market share. Technological issues include the latesttrends and developments. The emerging market for enzyme inhibitors includes countries such asIndia, China, Japan, Korea, Taiwan, Canada, Africa, Australia, New Zealand and Mexico.
  3. 3. METHODOLOGYBCC conducted a comprehensive literature search, which included technical newsletters andjournals, and many other sources. Data were collected through interviews and correspondencewith manufacturers of enzyme inhibitors’ technical experts. Projections were based on estimatessuch as the current number of end users, potential end users, mergers and acquisitions, andmarket trends.INFORMATION SOURCESMany companies within the industry were surveyed to obtain data for this study. Included weremanufacturers and end users of enzyme inhibitors in therapeutic categories and various diseasesectors industries. Data were gathered from various industry sources. BCC spoke with officialswithin the industry, consulted newsletters, company literature, product literature and a host oftechnical articles, journals, indexes and abstracts. Exhaustive investigations of databases by keyterminology were completed. In addition, data were compiled from current financial, trade andgovernment sources.Get your copy of this report @http://www.reportsnreports.com/reports/195544-global-markets-for-treatments-for-syndromes-of-dementia-and-movement-disorders.htmlMajor points covered in Table of Contents of this report includeTable Of ContentsChapter- 1: Introduction - Complimentary 3Study ObjectivesReasons For Doing This StudyContributions Of The Study And For WhomScope Of The StudyMethodologyInformation SourcesAbout The AuthorRelated Bcc Research ReportsBcc Online ServicesDisclaimerChapter- 2: Executive Summary 2Table Summary : Global Market For Treatments For Syndromes Of Dementia And MovementDisorders, Through 2017Figure Summary : Global Market For Treatments For Syndromes Of Dementia And MovementDisorders, 2010-2017
  4. 4. Chapter- 3: Overview 10The BrainClassification Of Neurodegenerative DisordersNeurodegenerative DisordersDiagnostic Tests For Neurodegenerative DisordersChapter- 4: Regulatory Aspects 5IntroductionDrug ApprovalsRegulatory Developments Affecting Syndromes Of Dementia And Movement Disorder ProductsChapter- 5: New Developments 19Table 6 : New Developments In Drugs Used To Treat Syndromes Of Dementia And MovementDisorders, 2012Table 7 : New Developments In Drugs Used To Treat Syndromes Of Dementia And MovementDisorders, 2011Table 8 : New Developments In Drugs Used To Treat Syndromes Of Dementia And MovementDisorders, 2010Chapter- 6: Global Markets 13Markets By Clinical/Pathological FeatureMarket By Disease TypeMarket By RegionMarkets By TechnologyChapter- 7: Market For Drug Products Used To Treat Progressive Dementia 32Market By Disease TypeMarket By RegionRegional Markets By Disease TypeMarket By TechnologyIndustry StructureChapter- 8: Market For Drugs To Treat Progressive Dementia With Other NeurologicalAbnormalities 24Market By Disease TypeMarket By RegionRegional Markets By Disease TypeMarket By TechnologyIndustry StructureChapter- 9: Market For Movement Disorder Syndromes 35
  5. 5. Market By Type Of DiseaseMarkets By RegionRegional Markets By Disease TypeMarket By TechnologyIndustry StructureChapter- 10: Patent Analysis 20Patents Issued By YearPatents By Disease CategoryPatents By Disease TypePatents By CountryPatents By CompanyChapter- 11: Current Situation 7Market TrendsOverall Drivers Of The Market For Treatments For Syndromes Of Dementia And MovementDisordersOther Factors Affecting The MarketCollaborations/Mergers And AcquisitionsChapter- 12: Company Profiles 55Abbott LaboratoriesAblynx NvAccera Inc.Acorda Therapeutics Inc.Actavis ElizabethAffiris AgAlliance Pharma PlcAllon Therapeutics Inc.AlphapharmAlzhyme Ltd.American Regent Inc.Apotex Inc.Apotheca Inc.Astellas Pharma Inc.Astrazeneca GmbhAurobindo Pharma Ltd.Baxter International Inc.Bellus Health Inc.Boehringer Ingelheim Ltd.Bristol-Myers SquibbBryant Ranch Prepack
  6. 6. Cadila Healthcare Ltd.Caraco Pharmaceutical LaboratoriesCardinal HealthCellzome AgCipla Ltd.Cognition Therapeutics Inc.Colucid Pharmaceuticals Inc.Comentis Inc.Cortex PharmaceuticalsCytos Biotechnology AgDaiichi Sankyo Co. Ltd.Dr. Reddys Laboratories Ltd.Eisai Co. Ltd.Elan Pharma International Ltd.Eli Lilly And Co.Endo Pharmaceuticals Inc.Envivo PharmaceuticalsEvotec AgEpitomics Inc.Exonhit Therapeutics SaForest Laboratories Inc.Glaxosmithkline PlcGlenmark Generics Ltd.H. Lundbeck A/SHameln Pharmaceuticals Ltd.Helicon Therapeutics Inc.Hospira Inc.Intellect Neurosciences Inc.Intra-Cellular Therapies Inc.Jazz Pharmaceuticals PlcMajor PharmaceuticalsMedivation Inc.Memory Pharmaceuticals Corp.Merck SeronoMerck Sharp & Dohme Ltd.Merz Pharma Gmbh & Co KgaaMithridion Inc.Mylan PharmaceuticalsNeuren Pharmaceuticals Ltd.Neuro-Hitech Inc.Neuroptix Corp.Neurosearch A/S
  7. 7. Newron Pharmaceuticals SpaNoscira SaNovartis AgNymox Pharmaceutical Corp.Orchid Chemicals & Pharmaceuticals Ltd.Orion Corp.Ortho-Mcneil Janssen Pharmaceuticals Inc.Par PharmaceuticalsPerrigo Co.Pfizer Inc.PharnextPhysicians Total Care Inc.Pliva Hrvatska D.O.O.Prasco LaboratoriesRanbaxy Laboratories Ltd.Roche Holding Ltd.Roxane Laboratories Inc.Sandoz International GmbhSanofiSanthera PharmaceuticalsShionogi & Co.Stada Arzneimittel AgSun PharmaTaj Pharmaceuticals Ltd.Takeda Pharmaceutical Co. Ltd.Tercica Inc.Teva Pharmaceutical Industries Ltd.Torrent PharmaUcb SaUdl LaboratoriesUpsher-Smith LaboratoriesValeant PharmaceuticalsVernalis PlcWatson Pharmaceuticals Inc.West-Ward PharmaceuticalChapter- 13: Appendix I: Abbreviations 3List Of TablesSummary Table : Global Market For Treatments For Syndromes Of Dementia And MovementDisorders, Through 2017
  8. 8. Table 1 : Classification Of Syndromes Of Dementia And Movement Disorders By PrimaryClinical/Pathological FeatureTable 2 : Anda And Nda Approvals Of Drugs Used To Treat Syndromes Of Dementia AndMovement Disorders, 2010 To March 2012Table 3 : Pending New Drug Applications For Drugs Used To Treat Syndromes Of Dementia AndMovement DisordersTable 4 : Fda Drug Safety Alerts, 2010 To March 2012Table 5 : Fda Recalls Of Drugs Used To Treat Syndromes Of Dementia And Movement Disorders,2010 To March 2012Table 6 : New Developments In Drugs Used To Treat Syndromes Of Dementia And MovementDisorders, 2012Table 7 : New Developments In Drugs Used To Treat Syndromes Of Dementia And MovementDisorders, 2011Table 8 : New Developments In Drugs Used To Treat Syndromes Of Dementia And MovementDisorders, 2010Table 9 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And MovementDisorders, Through 2017Table 10 : Global Market Shares Of Drug Products Used To Treat Neurodegenerative DisordersBy Clinical/Pathological Feature, 2011Table 11 : Global Sales Of Drug Products Used To Treat Major Neurodegenerative Disorders,Through 2017Table 12 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia AndMovement Disorders By Disease Type, 2011Table 13 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And MovementDisorders By Region, Through 2017Table 14 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia AndMovement Disorders By Region, 2011Table 15 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And MovementDisorders By Technology, Through 2017Table 16 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia AndMovement Disorders By Technology, 2011Table 17 : Global Sales Of Drug Products Used To Treat Progressive Dementia, Through 2017Table 18 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia ByDisease Type, 2011Table 19 : Global Sales Of Drug Products Used To Treat Progressive Dementia By Region,Through 2017Table 20 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia ByRegion, 2011Table 21 : Global Sales Of Drug Products Used To Treat Alzheimer’s Disease By Region, Through2017Table 22 : Global Sales Of Drug Products Used To Treat Lewy Body Dementia By Region,Through 2017
  9. 9. Table 23 : Global Sales Of Drug Products Used To Treat Pick’s Disease By Region, Through 2017Table 24 : Global Sales Of Drug Products Used To Treat Progressive Dementia By Technology,Through 2017Table 25 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia ByTechnology, 2011Table 26 : Leading Manufacturers/Distributors Of Drugs/Therapies Used To Treat AlzheimersDiseaseTable 27 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Alzheimer’sDisease, 2011Table 28 : Leading Manufacturers/Distributors Of Drugs/Therapies Used To Treat Lewy BodyDementiaTable 29 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Lewy BodyDementia, 2011Table 30 : Leading Manufacturers/ Distributors Of Drugs/Therapies Used To Treat Pick’s DiseaseTable 31 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Pick’sDisease, 2011Table 32 : Chdi Foundations’ Key Developments In Treating Huntington’s DiseaseTable 33 : Global Sales Of Drug Products Used To Treat Progressive Dementia With OtherNeurological Abnormalities By Type Of Disease, Through 2017Table 34 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia WithOther Neurological Abnormalities By Disease Type, 2011Table 35 : Global Sales Of Drug Products Used To Treat Progressive Dementia With OtherNeurological Abnormalities By Region, Through 2017Table 36 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia WithOther Neurological Abnormalities By Region, 2011Table 37 : Global Sales Of Drug Products Used To Treat Huntington’s Disease By Region,Through 2017Table 38 : Global Sales Of Drugs Used To Treat Corticobasal Ganglionic Degeneration ByRegion, Through 2017Table 39 : Global Sales Of Drug Products Used To Treat Progressive Dementia With OtherNeurological Abnormalities By Technology, Through 2017Table 40 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia WithOther Neurological Abnormalities By Technology, 2011Table 41 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Huntington’sDiseaseTable 42 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat HuntingtonsDisease, 2011Table 43 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Huntington’sDiseaseTable 44 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat CorticobasalGanglionic Degeneration, 2011Table 45 : Global Sales Of Drug Products Used To Treat Movement Disorder Syndromes By
  10. 10. Disease Type, Through 2017Table 46 : Global Market Shares Of Drug Products Used To Treat Movement Disorder SyndromesBy Disease Type, 2011Table 47 : Global Sales Of Drugs Used To Treat Movement Disorder Syndromes By Region,Through 2017Table 48 : Global Market Shares Of Drug Products Used To Treat Movement Disorder SyndromesBy Region, 2011Table 49 : Global Sales Of Drug Products Used To Treat Parkinson’s Disease By Region, Through2017Table 50 : Global Sales Of Drug Products Used To Treat Multiple System Atrophy By Region,Through 2017Table 51 : Global Sales Of Drug Products Used To Treat Progressive Supranuclear Palsy ByRegion, Through 2017Table 52 : Global Sales Of Drug Products Used To Treat Hallervorden-Spatz Disease By Region,Through 2017Table 53 : Global Sales Of Drug Products Used To Treat Movement Disorder Syndromes ByTechnology, Through 2017Table 54 : Global Market Shares Of Drug Products Used To Treat Movement Disorder SyndromesBy Technology, 2011Table 55 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Parkinson’sDiseaseTable 56 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Parkinson’sDisease, 2011Table 57 : Leading Manufacturers/Distributors Of Drugs/Therapies Used To Treat Multiple SystemAtrophyTable 58 : Manufacturers/Distributor Market Shares Of Drug Products Used To Treat MultipleSystem Atrophy, 2011Table 59 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat ProgressiveSupranuclear PalsyTable 60 : Manufacturers/Distributor Market Shares Of Drug Products Used To Treat ProgressiveSupranuclear Palsy, 2011Table 61 : Leading Manufacturers/Suppliers Of Drugs/Therapies Used To Treat Hallervorden-Spatz DiseaseTable 62 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Hallervorden-Spatz Disease, 2011Table 63 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And MovementDisorders Issued Per Year, 2010-March 2012Table 64 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And MovementDisorders By Category Of Disease, 2010-March 2012Table 65 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia)By Clinical/Pathological Feature, 2010-March 2012Table 66 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Disease
  11. 11. Type, 2010-March 2012Table 67 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (Progressive Dementia)By Patent Holder’s Country, 2010-March 2012Table 68 : U.S. Patent Shares Of Drugs Used To Treat Progressive Dementia By Patent Holder’sCountry, 2010-March 2012Table 69 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By PatentHolder’s Country, 2010-March 2012Table 70 : U.S. Patent Shares Of Drugs Used To Treat Movement Disorder Syndromes By PatentHolder’s Country, 2010-March 2012Table 71 : Number Of U.S. Patents On Drugs Used To Treat Syndromes Of Dementia(Progressive Dementia) By Company, 2010-March 2012Table 72 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By Company,2010-March 2012List Of FiguresSummary Figure : Global Market For Treatments For Syndromes Of Dementia And MovementDisorders, 2010-2017Figure 1 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And MovementDisorders, 2010-2017Figure 2 : Global Market Shares Of Drug Products Used To Treat Neurodegenerative DisordersBy Clinical/Pathological Feature, 2011Figure 3 : Global Sales Of Drug Products Used To Treat Major Neurodegenerative Disorders,2010-2017Figure 4 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia AndMovement Disorders By Disease, 2011Figure 5 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And MovementDisorders By Region, 2010-2017Figure 6 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia AndMovement Disorders By Region, 2011Figure 7 : Global Sales Of Drug Products Used To Treat Syndromes Of Dementia And MovementDisorders By Technology, 2010-2017Figure 8 : Global Market Shares Of Drug Products Used To Treat Syndromes Of Dementia AndMovement Disorders By Technology, 2011Figure 9 : Global Sales Of Drug Products Used To Treat Progressive Dementia, 2010-2017Figure 10 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia ByDisease Type, 2011Figure 11 : Global Sales Of Drug Products Used To Treat Progressive Dementia By Region, 2010-2017Figure 12 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia ByRegion, 2011Figure 13 : Global Sales Of Drug Products Used To Treat Alzheimer’s Disease By Region, 2010-
  12. 12. 2017Figure 14 : Global Sales Of Drug Products Used To Treat Lewy Body Dementia By Region, 2010-2017Figure 15 : Global Sales Of Drug Products Used To Treat Pick’s Disease By Region, 2010-2017Figure 16 : Global Sales Of Drug Products Used To Treat Progressive Dementia By Technology,2010-2017Figure 17 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia ByTechnology, 2011Figure 18 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Alzheimer’sDisease, 2011Figure 19 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Lewy BodyDementia, 2011Figure 20 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Pick’sDisease, 2011Figure 21 : Global Sales Of Drug Products Used To Treat Progressive Dementia With OtherNeurological Abnormalities By Type Of Disease, 2010-2017Figure 22 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia WithOther Neurological Abnormalities By Disease Type, 2011Figure 23 : Global Sales Of Drug Products Used To Treat Progressive Dementia With OtherNeurological Abnormalities By Region, 2010-2017Figure 24 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia WithOther Neurological Abnormalities By Region, 2011Figure 25 : Global Sales Of Drugs Used To Treat Huntington’s Disease By Region, 2010-2017Figure 26 : Global Sales Of Drugs Used To Treat Corticobasal Ganglionic Degeneration ByRegion, Through 2017Figure 27 : Global Sales Of Drug Products Used To Treat Progressive Dementia With OtherNeurological Abnormalities By Technology, 2010-2017Figure 28 : Global Market Shares Of Drug Products Used To Treat Progressive Dementia WithOther Neurological Abnormalities By Technology, 2011Figure 29 : Manufacturer/Distributor Market Shares Of Drug Products For Used To TreatHuntington’s Disease, 2011Figure 30 : Manufacturer/Distributor Market Shares Of Drugs Used To Treat CorticobasalGanglionic Degeneration, 2011Figure 31 : Global Sales Of Drug Products Used To Treat Movement Disorder Syndromes ByDisease Type, 2010-2017Figure 32 : Global Market Shares Of Drug Products Used To Treat Movement DisorderSyndromes By Disease Type, 2011Figure 33 : Global Sales Of Drug Products Used To Treat Movement Disorder Syndromes ByRegion, 2010-2017Figure 34 : Global Market Shares Of Drug Products Used To Treat Movement DisorderSyndromes By Region, 2011Figure 35 : Global Sales Of Drug Products Used To Treat Parkinson’s Disease By Region, 2010-
  13. 13. 2017Figure 36 : Global Sales Of Drug Products Used To Treat Multiple System Atrophy By Region,2010-2017Figure 37 : Global Sales Of Drug Products Used To Treat Progressive Supranuclear Palsy ByRegion, 2010-2017Figure 38 : Global Sales Of Drug Products Used To Treat Hallervorden-Spatz Disease By Region,2010-2017Figure 39 : Global Sales Of Drug Products Used To Treat Movement Disorder Syndromes ByTechnology, 2010-2017Figure 40 : Global Market Shares Of Drug Products Used To Treat Movement DisorderSyndromes By Technology, 2011Figure 41 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Parkinson’sDisease, 2011Figure 42 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat MultipleSystem Atrophy, 2011Figure 43 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat ProgressiveSupranuclear Palsy, 2011Figure 44 : Manufacturer/Distributor Market Shares Of Drug Products Used To Treat Hallervorden-Spatz Disease, 2011Figure 45 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And MovementDisorders Issued Per Year, 2010—March 2012Figure 46 : Percentage Of U.S. Patents On Drugs Used To Treat Syndromes Of Dementia AndMovement Disorders Issued Per Year, 2010-March 2012Figure 47 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia And MovementDisorders By Category Of Disease, 2010-March 2012Figure 48 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia ByClinical/Pathological Feature, 2010-March 2012*Figure 49 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By DiseaseType, 2010-March 2012Figure 50 : U.S. Patents On Drugs Used To Treat Syndromes Of Dementia (ProgressiveDementia) By Patent Holder’s Country, 2010-March 2012Figure 51 : U.S. Patents On Drugs Used To Treat Movement Disorder Syndromes By PatentHolder’s Country, 2010-March 2012Contact: sales@reportsandreports.com for more information.

×